A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer

Anticancer Research

Volumn 21, Issue 2 B, 2001, Pages 1385-1390

  Lin, C C ^a   Hsu, C H ^a   Chen, J ^a   Tsai, T C ^a   Cheng, A L ^a   Pu, Y S ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

5 Fluorouracil; Chemotherapy; Doxorubicin; Prostatic neoplasms; Tamoxifen

Indexed keywords

DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DRUG TOLERABILITY; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN THROMBOSIS; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAMOXIFEN; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0035021709     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Prostate cancer: Screening, diagnosis, and management
2. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
3. New agents in the therapy of hormone-refractory prostate cancer
4. Weekly doxorubicin in endocrine refractory carcinoma of the prostate
5. Phase II trial of doxorubicin in bidimentionally measurable prostatic adenocarcinoma
6. A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostate carcinoma
7. Doxorubicin, mitomycin C, and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study
8. Phase II studt of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer
9. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer
10. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: An Eastern Cooperative Oncology Group phase II study (E1889)
11. A phase II study of weekly 24-hour infusion with high-dose fluorouracil and leucovorin in colorectal carcinoma
12. Fluorouracil in colorectal cancer - A tale of two drugs: Implications of biochemical modulation
13. Weekly 24-hour infusion of high-dose 5- fluorouracil and leucovorin in the treatment of advanced gastric cancer: An effective and low-toxic regimen for patients with poor general condition
14. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma
15. Cisplatin, etoposide, and weekly high- dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
16. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers
17. Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer
18. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer
19. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma
20. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma
21. High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable non-small cell lung carcinoma
22. Toxicity and response criteria of the Eastern Cooperative Oncology Group
23. Acute confusion induced by high-dosage infusion of 5-fluorouracil and folinic acid
24. High-dose 5-fluorouracil infusional therapy is associate with hyperammonaenmia, lactic acidosis and encephalopathy
25. Chemotherapy with mitoxantrone plus prednisolone or prednisolone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
26. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia Group B 9182 study
27. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory cancer: A Hoosier Oncology Group and Fox Chase Network Phase III trial
28. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone
29. Mitomycin-C for metastatic prostate cancer: Final analysis of a randomized trial
30. Response criteria in prostatic carcinoma
31. Prostate -specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
32. Evaluation of prostate specific antigen as a surrogate marker for response of hormone refractory prostate cancer to suramin therapy
33. Change in serum prostate- specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer